Plain-English translation of NCT07401992 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether semaglutide, a medication already used to treat type 2 diabetes and obesity, might also help improve psoriasis—a chronic inflammatory skin condition. The researchers believe that semaglutide's anti-inflammatory properties could reduce both skin symptoms and the underlying inflammation that contributes to psoriasis. You would receive either the medication or a placebo (inactive pill) alongside a topical skin cream for 12 weeks.
Psoriasis often occurs alongside obesity and diabetes, and research suggests these conditions share common inflammatory pathways. Since this medication has already shown anti-inflammatory benefits for diabetes and weight management, doctors want to see whether it could also help calm psoriasis and improve quality of life for patients dealing with multiple conditions at once.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic at baseline and then at weeks 4, 8, and 12. At each visit, your skin would be examined and measured using a standardized scoring system. You would also complete questionnaires about how psoriasis affects your quality of life, and blood samples would be taken at the start and end to measure inflammation markers. For 12 weeks, you would take either the medication or a placebo pill by mouth once daily, and use a prescribed topical cream on your skin.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Mexico